Chronic hemodialysis using venipuncture and surgically created arteriovenous fistula. New Eng. J. Med. 275:1089–1092, 1966. Select the format you want to export the citation of this publication.

Governor Dennis Pineda's plan to bring affordable dialysis services closer to the Kapampangans is now starting to become a reality.This, as the provincial gover ...

Autologous arteriovenous access is the key to long-term success with hemodialysis and is strongly supported by the National Kidney Foundation's Dialysis Outcomes Quality Initiative guidelines.

Systems announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy trial ...

A research team led by Professor Park Hoon-seok of Nephrology at Catholic University of Korea's Seoul St. Mary's Hospital and clinical instructor Ryu Se-young at Incheon St. Mary's Hospital recently ...

Q4 2024 Earnings Call Transcript March 28, 2025 Humacyte, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.23. Operator: Good morning, ladies and gentlemen. Welcome to ...

Going beyond the trauma indication, we're also very excited about the ATEV program right behind it, which is in dialysis access ... 12 months as compared to AV fistula, which is the current ...

Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of SYMVESS™ in the vascular trauma indication, the development of the product candidates ...

FDA Approval: The FDA granted full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...

The WRAPSODY CIE received premarket approval (PMA) from the US Food and Drug Administration (FDA) in December 2024. Merit began commercialization of the device in the United States in January 2025.

Transparent, well-designed clinical trials are a must. FastWave Medical's Scott Nelson has advice on how to get there.